AFXD Stock Overview
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Carl Zeiss Meditec AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €97.43 |
52 Week High | €116.40 |
52 Week Low | €78.53 |
Beta | 0.90 |
1 Month Change | -16.19% |
3 Month Change | n/a |
1 Year Change | -18.88% |
3 Year Change | -29.86% |
5 Year Change | 12.31% |
Change since IPO | 364.04% |
Recent News & Updates
Recent updates
Shareholder Returns
AFXD | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 0% | 1.9% | 0.7% |
1Y | -18.9% | -9.2% | 3.0% |
Return vs Industry: AFXD underperformed the UK Medical Equipment industry which returned -9.2% over the past year.
Return vs Market: AFXD underperformed the UK Market which returned 3% over the past year.
Price Volatility
AFXD volatility | |
---|---|
AFXD Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 6.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AFXD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AFXD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1846 | 4,823 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Carl Zeiss Meditec AG Fundamentals Summary
AFXD fundamental statistics | |
---|---|
Market cap | €8.75b |
Earnings (TTM) | €276.80m |
Revenue (TTM) | €2.09b |
31.6x
P/E Ratio4.2x
P/S RatioIs AFXD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AFXD income statement (TTM) | |
---|---|
Revenue | €2.09b |
Cost of Revenue | €893.14m |
Gross Profit | €1.20b |
Other Expenses | €924.07m |
Earnings | €276.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | 3.09 |
Gross Margin | 57.35% |
Net Profit Margin | 13.22% |
Debt/Equity Ratio | 7.2% |
How did AFXD perform over the long term?
See historical performance and comparison